Table 2.
Characteristics of the external testing set.
| Overall, N = 13,988 | No events, N = 12,026 | Acute Coronary Syndrome, N = 361 | Death, N = 683 | Revasc., N = 918 | p value | |
|---|---|---|---|---|---|---|
| Age | 67 (59, 75) | 66 (58, 74) | 69 (61, 77) | 73 (65, 80) | 69 (61, 75) | <0.001a |
| Male | 7621 (54%) | 6309 (52%) | 237 (66%) | 414 (61%) | 661 (72%) | <0.001b |
| BMI | 29 (26, 34) | 29 (26, 34) | 29 (25, 33) | 28 (24, 32) | 29 (26, 33) | <0.001a |
| Post PCI | 1387 (9.9%) | 1030 (8.6%) | 101 (28%) | 84 (12%) | 172 (19%) | <0.001b |
| Post TAVR | 9 (<0.1%) | 5 (<0.1%) | 0 (0%) | 0 (0%) | 4 (0.4%) | 0.009b |
| Past CABG | 843 (6.0%) | 602 (5.0%) | 59 (16%) | 64 (9.4%) | 118 (13%) | <0.001b |
| Hypertension | 8921 (64%) | 7477 (62%) | 264 (73%) | 482 (71%) | 698 (76%) | <0.001b |
| Diabetes Mellitus | 4023 (29%) | 3240 (27%) | 151 (42%) | 235 (34%) | 397 (43%) | <0.001b |
| Dyslipidemia | 4635 (33%) | 3982 (33%) | 161 (45%) | 270 (40%) | 222 (24%) | <0.001b |
| Family History | 2496 (18%) | 2228 (19%) | 88 (24%) | 120 (18%) | 60 (6.5%) | <0.001b |
| Stress test type: Exercise | 7069 (51%) | 6395 (53%) | 112 (31%) | 146 (21%) | 416 (45%) | <0.001b |
| Stress test type: Pharmacologic | 6919 (49%) | 5631 (47%) | 249 (69%) | 537 (79%) | 502 (55%) | <0.001b |
| Resting Heart Rate | 73 (64, 83) | 73 (64, 83) | 71 (63, 80) | 75 (66, 85) | 72 (64, 82) | <0.001a |
| Stress heart rate-peak | 126 (97, 146) | 129 (100, 148) | 100 (83, 131) | 98 (83, 120) | 121 (96, 137) | <0.001a |
| Stress Systolic BP-peak | 157 (134, 178) | 159 (136, 180) | 146 (125, 165) | 132 (113, 152) | 158 (134, 178) | <0.001a |
| Extent of perfusion abnormality (%) | 2.9 (1.1, 6.2) | 2.6 (1.0, 5.5) | 5.8 (2.2, 12.2) | 4.8 (1.8, 10.8) | 6.8 (3.3, 13.7) | <0.001a |
Statistics presented: median (interquartile range), n (%); Statistical tests used:
aKruskal-Wallis rank sum test.
bFisher’s exact test; Abbreviations: Revasc. revascularization, BMI body mass index, BP blood pressure, CABG coronary artery bypass grafting, CABG coronary artery bypass grafting, TAVR transcutaneous aortic valve replacement.